Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib Combined With Sonrotoclax in B-Cell Lymphoma
NCT07744750Phase 2Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirtobrutinib and sonrotoclax in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more (3 cohorts), sponsored by Changzhou Second People's Hospital. Primary endpoint: Objective Response Rate at week 56. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pirtobrutinibsonrotoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07744750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744750.